Skip to content

Study · Animal study (in vivo) · dog · 2018

7 results

Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide.

Sabbah HN, Gupta RC, Singh-Gupta V, Zhang K, Lanfear DE

Cardiovascular drugs and therapy1 Aug 2018Cited by 76 (Europe PMC)

PMID29951944 (opens in a new tab)PMCIDPMC6133191 (opens in a new tab)DOI10.1007/s10557-018-6805-y (opens in a new tab)PepBankPUB-29951944
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

PurposeAbnormalities of MITO dynamics occur in HF and have been implicated in disease progression. This study describes the broad range abnormalities of mitochondrial (MITO) dynamics in Heart Failure with reduced ejection fraction (HF) and evaluates the effects of long-term therapy with elamipretide (ELAM), a MITO-targeting peptide, on these abnormalities.MethodsStudies were performed in left ventricular tissue from dogs and humans with HF, and were compared with tissue from healthy dogs and healthy donor human hearts. Dogs with HF were randomized to 3 months therapy with ELAM or vehicle. The following were evaluated in dog and human hearts: (1) regulators of MITO biogenesis, including endothelial nitric oxide synthase (eNOS), cyclic guanosine monophosphate (cGMP), and peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α, a transcription factor that drives MITO biogenesis); (2) regulators of MITO fission and fusion, including fission-1, dynamin-related protein-1, mitofusion-2, dominant optic atrophy-1, and mitofilin; and (3) determinants of cardiolipin (CL) synthesis and remodeling, including CL synthase-1, tafazzin-1, and acyl-CoA:lysocardiolipin acyltransferase-1.ResultsThe study showed decreased levels of eNOS, cGMP, and PGC-1α in HF (dog and human). Increased levels of fission-associated proteins, decreased levels of fusion-associated proteins, decreased mitofilin, and abnormalities of CL synthesis and remodeling were also observed. In all instances, these maladaptations were normalized following long-term therapy with ELAM.ConclusionsCritical abnormalities of MITO dynamics occur in HF and are normalized following long-term therapy with ELAM. The findings provide support for the continued development of ELAM for the treatment of HF.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In dogs with heart failure, 3 months of elamipretide normalized the decreased eNOS level.

    In plain wordsIn dogs with heart failure, elamipretide brought a low level of eNOS back to normal.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseeNOS level
    Study

    dogn: not reported in source

    dogs with heart failure
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    In all instances, these maladaptations were normalized following long-term therapy with ELAM.
    2 context sentences
    Summary · context
    The study showed decreased levels of eNOS, cGMP, and PGC-1α in HF (dog and human).
    Summary · context
    Dogs with HF were randomized to 3 months therapy with ELAM or vehicle.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In dogs with heart failure, 3 months of elamipretide normalized the decreased cGMP level.

    In plain wordsIn dogs with heart failure, elamipretide brought a low level of cGMP back to normal.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreasecGMP level
    Study

    dogn: not reported in source

    dogs with heart failure
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    In all instances, these maladaptations were normalized following long-term therapy with ELAM.
    2 context sentences
    Summary · context
    The study showed decreased levels of eNOS, cGMP, and PGC-1α in HF (dog and human).
    Summary · context
    Dogs with HF were randomized to 3 months therapy with ELAM or vehicle.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In dogs with heart failure, 3 months of elamipretide normalized the decreased PGC-1α level.

    In plain wordsIn dogs with heart failure, elamipretide brought a low level of PGC-1α back to normal.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreasePGC-1α level
    Study

    dogn: not reported in source

    dogs with heart failure
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    In all instances, these maladaptations were normalized following long-term therapy with ELAM.
    2 context sentences
    Summary · context
    The study showed decreased levels of eNOS, cGMP, and PGC-1α in HF (dog and human).
    Summary · context
    Dogs with HF were randomized to 3 months therapy with ELAM or vehicle.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In dogs with heart failure, 3 months of elamipretide normalized the increased levels of fission-associated proteins.

    In plain wordsIn dogs with heart failure, elamipretide brought raised levels of mitochondrial fission proteins back to normal.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseFission-associated proteins
    Study

    dogn: not reported in source

    dogs with heart failure
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    In all instances, these maladaptations were normalized following long-term therapy with ELAM.
    2 context sentences
    Summary · context
    Increased levels of fission-associated proteins, decreased levels of fusion-associated proteins, decreased mitofilin, and abnormalities of CL synthesis and remodeling were also observed.
    Summary · context
    Dogs with HF were randomized to 3 months therapy with ELAM or vehicle.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In dogs with heart failure, 3 months of elamipretide normalized the decreased levels of fusion-associated proteins.

    In plain wordsIn dogs with heart failure, elamipretide brought low levels of mitochondrial fusion proteins back to normal.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseFusion-associated proteins
    Study

    dogn: not reported in source

    dogs with heart failure
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    In all instances, these maladaptations were normalized following long-term therapy with ELAM.
    2 context sentences
    Summary · context
    Increased levels of fission-associated proteins, decreased levels of fusion-associated proteins, decreased mitofilin, and abnormalities of CL synthesis and remodeling were also observed.
    Summary · context
    Dogs with HF were randomized to 3 months therapy with ELAM or vehicle.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In dogs with heart failure, 3 months of elamipretide normalized the decreased mitofilin level.

    In plain wordsIn dogs with heart failure, elamipretide brought a low level of mitofilin back to normal.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitofilin level
    Study

    dogn: not reported in source

    dogs with heart failure
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    In all instances, these maladaptations were normalized following long-term therapy with ELAM.
    2 context sentences
    Summary · context
    Increased levels of fission-associated proteins, decreased levels of fusion-associated proteins, decreased mitofilin, and abnormalities of CL synthesis and remodeling were also observed.
    Summary · context
    Dogs with HF were randomized to 3 months therapy with ELAM or vehicle.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In dogs with heart failure, 3 months of elamipretide normalized the abnormalities of cardiolipin synthesis and remodeling.

    In plain wordsIn dogs with heart failure, elamipretide brought abnormal cardiolipin synthesis and remodeling back to normal.

    Peptide
    Elamipretide (SS-31)
    Outcome
    MixedCardiolipin synthesis and remodeling
    Study

    dogn: not reported in source

    dogs with heart failure
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · 3 monthsAs given in this study (dog).

    Source sentences

    Summary
    In all instances, these maladaptations were normalized following long-term therapy with ELAM.
    2 context sentences
    Summary · context
    Increased levels of fission-associated proteins, decreased levels of fusion-associated proteins, decreased mitofilin, and abnormalities of CL synthesis and remodeling were also observed.
    Summary · context
    Dogs with HF were randomized to 3 months therapy with ELAM or vehicle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.